Hypovolemic Phlebotomy in Living Donor Liver Transplant

Intraoperative Phlebotomy in Living Donor Liver Transplant- Means to Minimize Blood Transfusion: A Randomized Controlled Trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099724

Enrollment

120

Registered

2025-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K70- Alcoholic liver disease Health Condition 2: K746- Other and unspecified cirrhosis ofliver Health Condition 3: K721- Chronic hepatic failure

Interventions

Intervention1: Controlled Hypovolemic phlebotomy: Patients who will undergo controlled hypovolemic phlebotomy Control Intervention1: Control Group: patients who will not undergo intraoperative phlebot

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients aged between 18-65years planned to undergo living donor liver transplant.

Exclusion criteria

Exclusion criteria: Patients who refuse to consent to participate in the study. Patients aged less than 18years of age. Patients of acute liver failure Patients planned for re-transplantation. Patients planned for combined procedure (SLKT, LT+CABG) Patients with preoperative haemoglobin less than 7.0 gm/dl Patients with EF less than 50% Patients with chronic kidney disease, eGFR less than 30ml/min/1.73m2 MDRD, H/O renal replacement therapy within last two weeks

Design outcomes

Primary

Measure	Time frame
To compare intraoperative red cell transfusion requirements (measured in units) between the groups.Timepoint: intraoperative period	—

Secondary

Measure	Time frame
Secondary Outcomes: Intraoperative fluid requirement [Crystalloids (ml); Colloids (ml) and 25% Albumin(ml)] Vasopressor requirement (Noradrenaline- mcg/kg/min and Vasopressin- total units) Incidence of postoperative renal dysfunction (KDIGO criteria- on POD1, POD3 and POD7) Evaluate pulmonary outcomes (duration of mechanical ventilation, pleural effusion requiring drainage within 72 hours postoperatively) between the groups. Timepoint: fluid and Vasopressor requirement- intraoperative period incidence of AKI- 7 days pulmonary outcomes- 3 days	—

Measure

Time frame

Secondary Outcomes: Intraoperative fluid requirement [Crystalloids (ml); Colloids (ml) and 25% Albumin(ml)] Vasopressor requirement (Noradrenaline- mcg/kg/min and Vasopressin- total units) Incidence of postoperative renal dysfunction (KDIGO criteria- on POD1, POD3 and POD7) Evaluate pulmonary outcomes (duration of mechanical ventilation, pleural effusion requiring drainage within 72 hours postoperatively) between the groups. Timepoint: fluid and Vasopressor requirement- intraoperative period incidence of AKI- 7 days pulmonary outcomes- 3 days

—

Countries

India

Contacts

Public ContactDr Prachi Gokula

Medanta, The Medicity

paachuG@gmail.com7579160753

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026